The endocannabinoid system appears to have an essential role in regulating basic human functions like sleep, eating, metabolism, and more. When this system is not functioning correctly, weight gain can occur. CBD helps to restore homeostasis to the cells of the body and can be very useful in reducing fat accumulation and subsequent health risks related to excess body weight.

By commenting on this post I agree to give source information for any health/medical information that is not my personal experience or general knowledge. I understand that personal experience is any symptom, test, treatment, etc. that I or a close family member has undergone himself/herself. I understand that my comment will not be approved unless I provide trustworthy sources for all statements regarding statistics, data, studies, and new advancement in medicine.
Most human studies of CBD have been done on people who have seizures, and the FDA recently approved the first CBD-based drug, Epidiolex, for rare forms of epilepsy. Clinical trials for other conditions are promising, but tiny. In one Brazilian study published in 2011 of people with generalized social anxiety disorder, for example, taking a 600-mg dose of CBD (higher than a typical dose from a tincture) lessened discomfort more than a placebo, but only a dozen people were given the pill.

But because all these products are illegal according to the federal government, cannabis advocates are cautious. “By and large, the federal government is looking the other way,” says Paul Armentano, deputy director of the Washington, DC–based National Organization for the Reform of Marijuana Laws (NORML), but until federal laws are changed, “this administration or a future one could crack down on people who produce, manufacture, or use CBD, and the law would be on its side.”
Cannabidiol is the major nonpsychoactive component of Cannabis sativa. Over the centuries, a number of medicinal preparations derived from C. sativa have been employed for a variety of disorders, including gout, rheumatism, malaria, pain, and fever. These preparations were widely employed as analgesics by Western medical practitioners in the 19th century (1). More recently, there is clinical evidence suggesting efficacy in HIV-associated neuropathic pain, as well as spasms associated with multiple sclerosis (1).
Unfortunately due to the disappointing and down right inaccurate position of the federal government in classifying Cannabis as a schedule one drug, most research institutions risk federal funding if they conduct real research on Cannabis. This has dramatically limited the potential for real research by real scientists to be conducted. That research is critical to better understanding the multitude of therapeutic effects of the various chemical constituents found in Cannabis.
CannabiGold was formulated by HemPoland but has recently been acquired for $15.5 million by The Green Organic Dutchman Holdings Ltd. (TGOD). On top of that, they’ve invested another $10 million in the development of the company. This is the largest cannabis oil Europe has seen yet. CannabiGold’s CO2 extracted oil comes from 1,250 acres of hemp fields in Poland and is widely distributed to 13 countries in Europe, namely: Poland, Austria, Netherlands, Germany, United Kingdom, Italy, Switzerland, Portugal, Ireland, Czech Republic, Slovenia, Lithuania, and Estonia. CannabiGold is one of the only companies in Europe with more than 700 bricks and mortar sales locations. Their goal is to be number 1 in Europe and it seems that they may make it! Founder and CEO Maciej Kowalski reached the peak of success by methodically researching, testing, and improving their full spectrum CBD oils, which range from the starter 5% to the strong 30% CBD oil. The latter comes with a free product gift and free priority delivery if you purchase it at for the Ageless. CannabiGold also features 10% and 15% oil.

Some CBD manufacturers have come under government scrutiny for wild, indefensible claims, such that CBD is a cure-all for cancer, which it is not. We need more research but CBD may be prove to be an option for managing anxiety, insomnia, and chronic pain. Without sufficient high-quality evidence in human studies we can’t pinpoint effective doses, and because CBD is currently is mostly available as an unregulated supplement, it’s difficult to know exactly what you are getting. If you decide to try CBD, talk with your doctor — if for no other reason than to make sure it won’t affect other medications you are taking.


Schizophrenia is a disorder that generally requires heavy antipsychotic drugs just to manage daily life. However, this systematic review notes that such drugs “provide limited cognitive benefits,” which is extremely rough given the side effects antipsychotic drugs can have. As discussed in the review, CBD may be a possible alternative to such heavy prescription drugs.
17. Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, Woodcock H, Dorward P, Pigliacampo B, Close S, Platt B, Riedel G. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behavior. Psychopharmacology (Berl) 2012;219:859–873. [PubMed] [Google Scholar]

Dietary changes are the most important action individuals can choose to get off the roller coaster. But CBD could lend a hand in the process. A 2018 study showed that the cannabinoids THC, CBD and CBN enhance cells’ ability to take up glucose. And they perform even better than metformin, a common pharmaceutical prescribed to lower elevated blood glucose.


Studies have demonstrated that CBD has a low affinity for the CB1 receptors, but even at low concentrations, CBD decreases G-protein activity (3). CB1 receptors are expressed on many glutamatergic synapses that have been implicated in seizure threshold modulation. CBD may act at CB1 receptors to inhibit glutamate release (4). Studies have shown changes in the expression of CB1 receptors during epileptogenesis and after recurrent seizures (5). CB1 receptor expression is upregulated at GABAergic synapses and shown to be downregulated at glutamatergic synapses in epilepsy, contributing to lowering seizure thresholds.

CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
Gloss and Vickrey conducted a Cochrane systematic review of the use of CBD in the treatment of epilepsy (11). Their methodology included only those trials that were randomized and controlled and excluded case series, case reports, and expert opinion. They were able to identify only 4 randomized controlled studies reported in the literature, and they included a letter to the editor and an abstract. The total number of subjects enrolled in these studies was 48 (11–14). While only four studies and a letter to the editor were in the actual analysis, the authors included a complete reference listing of all articles reviewed for inclusion.
Under federal law, cannabis (from which both CBD and marijuana are derived) is illegal everywhere, although the laws against it aren’t generally enforced in states that have legalized marijuana. Some manufacturers claim that CBD culled from legally imported industrial hemp, which has little to no THC, is fine to ship across the U.S., but many experts disagree, noting that because hemp comes from the same species as marijuana, cannabis sativa, all CBD falls under the DEA’s Schedule 1 designation. “This creative interpretation of the law runs afoul of reality,” says the Brookings Institution, a Washington, DC, think tank.

This method proved successful for years, but high-strength concentrates would sometimes crystallise and clog the very small orifice through which the oil was to be delivered. Recognising the issue and the fact that most customers needed a higher dose to be delivered quickly, CannabiGold further developed its packaging to launch a side nozzle. This pump can deliver a higher dose of the oil (4 times what it used to) in one go and do it very easily under the tongue, without having to use a mirror to ensure one is getting the right number of drops. The easy dropper technology has boosted the good reputation of the already popular cylinder bottles because they’re easy and safe to use wherever you go with no leaking and a very convenient pocket size. Each of their 12g bottles now contains 100 pumps (full doses) of CBD, making it the easiest and most convenient system available, truly suitable for all use, including travel. Visit the CannabiGold collection.
×